Cargando…

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY

SIMPLE SUMMARY: This prospective phase II trial evaluated the safety and efficacy of direct oral anticoagulants (DOACs) versus subcutaneous dalteparin for cancer-associated venous thromboembolism (CA-VTE) in patients with high-risk cancer types and currently active advanced cancers. The clinically r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jwa Hoon, Yoo, Changhoon, Seo, Seyoung, Jeong, Jae Ho, Ryoo, Baek-Yeol, Kim, Kyu-pyo, Lee, Jung Bok, Lee, Keun-Wook, Kim, Ji-Won, Kim, Il-Hwan, Kang, Myoungjoo, Ryu, Hyewon, Cheon, Jaekyung, Park, Sook Ryun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833795/ https://www.ncbi.nlm.nih.gov/pubmed/35158827 http://dx.doi.org/10.3390/cancers14030559

Ejemplares similares

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005)

Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
por: Rommers, Mirjam K, et al.
Publicado: (2006)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
por: Yoo, Changhoon, et al.
Publicado: (2019)

Dalteparin-sodium: Chest wall haematoma: case report
Publicado: (2022)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023)

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment
por: Woodruff, Seth, et al.
Publicado: (2016)

Hypoxia and the Anticoagulants Dalteparin and Acetylsalicylic Acid Affect Human Placental Amino Acid Transport
por: Kleppa, Marc-Jens, et al.
Publicado: (2014)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017)

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
por: Becattini, Cecilia, et al.
Publicado: (2021)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers
por: Gadiko, C., et al.
Publicado: (2013)

Quantitative Imaging in Pediatric Hepatobiliary Disease
por: Yoon, Haesung, et al.
Publicado: (2019)

Update on Hepatobiliary Plasticity
por: Kim, Minwook, et al.
Publicado: (2023)

Bilateral spontaneous, simultaneous lower extremity hematomas in a patient on dalteparin()
por: Daggett, J.R., et al.
Publicado: (2013)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study
por: Park, Kwonoh, et al.
Publicado: (2017)

Real-world data analysis of patients with cancer of unknown primary
por: Kang, Sora, et al.
Publicado: (2021)

A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris
por: Amane, Hanmant S., et al.
Publicado: (2011)

CCN1 in hepatobiliary injury repair
por: Kim, Ki-Hyun, et al.
Publicado: (2015)

The outcome of endoscopic management of bile leakage after hepatobiliary surgery
por: Yun, Seon Ung, et al.
Publicado: (2017)

Three-dimensional imaging for hepatobiliary and pancreatic diseases: Emphasis on clinical utility
por: Kim, Soo Jin, et al.
Publicado: (2009)

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3(−) CD4(+) T Cells in Biliary Tract Cancer
por: Kim, Hyung-Don, et al.
Publicado: (2021)

Effect of a Direct Thrombin Inhibitor Compared with Dalteparin and Unfractionated Heparin on Human Osteoblasts
por: Winkler, Tobias, et al.
Publicado: (2011)

Structural Characterization of the Low-Molecular-Weight Heparin Dalteparin by Combining Different Analytical Strategies
por: Bisio, Antonella, et al.
Publicado: (2017)

Unusual Presentation of Subcutaneous Phaeohyphomycosis by Alternaria alternate
por: Lee, Ji Yeon, et al.
Publicado: (2019)

Classification of hepatobiliary scintigraphy patterns in segmented gallbladder according to anatomical discordance
por: Lee, Yun-Chae, et al.
Publicado: (2023)

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3hiu35v49vv1l7ps5ucn344lvj